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Abstract  1 
Prescription drug spending is growing faster than any other sector of healthcare. 2 
However, very little is known about patterns of prescribing and cost of prescribing 3 
between general practices. In this study, we examined variation in prescription rates 4 
and prescription costs through time for 55 GP surgeries in Northern Ireland Western 5 
Health and Social Care Trust. Temporal changes in variability of prescribing rates and 6 
costs were assessed using the Mann–Kendall test. Outlier practices contributing to 7 
between practice variation in prescribing rates were identified with the interquartile 8 
range outlier detection method. The relationship between rates and cost of prescribing 9 
was explored with Spearman's statistics. The differences in variability and mean 10 
number of prescribing rates associated with the practice setting and socioeconomic 11 
deprivation were tested using t-test and F-test, respectively. The largest between-12 
practice difference in prescribing rates was observed for Apr-Jun 2015, with the 13 
number of prescriptions ranging from 3.34 to 8.36 per patient. We showed that 14 
practices with outlier prescribing rates greatly contributed to between-practice 15 
variability. The largest difference in prescribing costs was reported for Apr-Jun 2014, 16 
with the prescription cost per patient ranging from £26.4 to £64.5. In addition, the 17 
temporal changes in variability of prescribing rates and costs were shown to undergo 18 
an upward trend. We demonstrated that practice setting and socio-economic 19 
deprivation accounted for some of the between-practice variation in prescribing. Rural 20 
practices had higher between practice variability than urban practices at all time points. 21 
Practices situated in more deprived areas had higher prescribing rates but lower 22 
variability than those located in less deprived areas. Further analysis is recommended 23 
to assess if variation in prescribing can be explained by demographic characteristics 24 
of patient population and practice features. Identification of other factors contributing 25 
to prescribing variability can help us better address potential inappropriateness of 26 
prescribing. 27 
Introduction  28 
In recent years, NHS spending on drugs has substantially risen, from £13.0 billion in 29 
2010/11 to £16.8 billion in 2015/16 [1]. Most of the expenditure on prescribed 30 
medicines is incurred in primary care and closely related to the steadily growing 31 
workload of general practitioners (GPs) [1]. In England, patient consultations with GPs 32 
increased by 16% in the period 2007-14 [2] whereas in Northern Ireland, the GPs 33 
workload grew by 22% over the same period [3]. In addition, there has been an 34 
approximately 60% increase in prescription items dispensed from 2005 to 2014 in 35 
Northern Ireland [3] and a corresponding 50.4% rise in the number of prescriptions 36 
dispensed in England [4].  37 
The National Audit Office report found that substantial savings for the NHS could be 38 
achieved by improving the overall quality and cost-effectiveness of prescribing [5]. 39 
Accordingly, a lot of interest has been focused on variation in prescribing practice as 40 
a potential source to save money [5,6]. Despite a wealth of literature on prescribing 41 
patterns [5,7,8,9], there is a lack of full understanding of factors that contribute to 42 
between-practice differences in prescribing. Among key influences upon prescribing 43 
variation, the demographic and socio-economic characteristics of patient population 44 
(e.g. age, ethnicity, deprivation) are most often acknowledged by researchers [10,11]. 45 
GP practices with a greater proportion of people in older age groups were more likely 46 
to prescribe minor tranquilisers [10], sex hormones, anticoagulants and protamine, 47 
and treatments for glaucoma [12]. Significant differences in prescribing were also 48 
associated with the level of deprivation [13]. Several studies have shown that extent 49 
of local deprivation influences antidepressant and lipid-lowering medication 50 
prescribing [14,15,16]. On the other hand, lower volume of prescribing was observed 51 
in practices with higher proportions of patients from ethnic minority populations [17]. 52 
Practice features were also among factors contributing to the variation in prescribing 53 
behaviour. Examples of that include higher prescription rates issued by practices 54 
located in urban areas with a greater proportion of female GPs [18]. Lower prescribing 55 
was found for single-handed practices, practices in rural areas, with a higher average 56 
age of general practitioners, and with GPs born outside the UK [15,19,20]. 57 
Differences in characteristics of GP practices or a patient population do not always 58 
explain GPs prescribing behaviour. In many cases, the variability in prescribing rates 59 
is associated with inefficient or inappropriate prescribing [5,21]. It has been estimated 60 
that the prescription costs could be reduced by as much as £1bn if unwarranted 61 
variations in prescribing levels were eliminated and the drugs were prescribed with the 62 
same standard [21]. Better efficiency and appropriateness in prescribing practice could 63 
be achieved by addressing the over- or under-utilisation of drugs. It was shown that 64 
prescribed medications are often taken for long periods beyond the point when they 65 
are needed and around 30% of drugs are abandoned by patients [22,23,24,25]. Major 66 
NHS savings could also be generated by using treatments that are most cost-effective. 67 
Moon et al. [26] showed that a large number of GPs are still prescribing brand name 68 
medications, even though the cheaper, equally safe and effective alternatives are 69 
available.  70 
The aim of this study was to investigate temporal changes in rates and costs of 71 
prescribing as well as between-practice variation in prescribing. In addition, we 72 
examined if prescribing rates of GPs were related to the practice setting and 73 
socioeconomic deprivation.  74 
Methods 75 
Data and pre-processing 76 
We analysed the number and actual cost of prescription items issued by 55 general 77 
practices within the Northern Ireland Western Health and Social Care Trust (WHSCT) 78 
during twelve consecutive periods of 3 months, starting from Apr 2013 to Mar 2016. 79 
The actual cost of prescriptions was defined as the estimated cost to the NHS 80 
calculated by subtracting the discount per item from the gross cost which is the basic 81 
price of a drug.  82 
The GP prescribing data was obtained from the Business Services Organisation’s 83 
(BSO) prescribing and dispensing information systems [27]. It includes prescribing for 84 
all GPs and other non-medical prescribers who are attached to GP practices i.e. 85 
nurses, pharmacists, optometrists, chiropodists, and radiographers. To allow temporal 86 
comparison of prescribing data, the number of drug prescriptions and their total cost 87 
calculated for each general practice was adjusted for the total number of patients in 88 
each practice and expressed as prescriptions/cost (£) per patient.  89 
Given data from the Census Office of the Northern Ireland Statistics and Research 90 
Agency [28], a practice was designated as urban if its postal address was situated in 91 
a settlement of more than 10,000 residents. Under this definition, 31 practices were 92 
categorised as urban and 24 as rural. 93 
In addition, practices were categorised based on the Northern Ireland Multiple 94 
Deprivation Measure (NIMDM) at the level of Super Output Area (SOA) [29]. The 95 
NIMDM consists of seven domains i.e. Income; Employment; Health, Deprivation, and 96 
Disability; Education, Skills and Training; Proximity to Services; Living Environment; 97 
and Crime and Disorder. On this overall measure, the SOA with a NIMDM rank of 1 is 98 
considered the most deprived, and 890 the least deprived. Accordingly, a practice 99 
situated in SOA with the NIMDM rank larger than 445 was designated as ‘located in a 100 
less deprived area’ while a practice situated in SOA with a NIMDM rank smaller than 101 
445 was designated as ‘located in a more deprived area’. Under this definition, we 102 
identified 11 practices ‘located in less deprived areas’ and 44 practices ‘located in 103 
more deprived areas’. 104 
Statistical analysis 105 
The variation in the number and cost of prescriptions per patient was assessed by 106 
calculating the variance (σ²) for each of the 12 considered time points [30]. In addition, 107 
we analysed changes in mean (µ) and range of the rate and cost of prescriptions.  108 
The outlier GP practices were identified for all time points using the interquartile range 109 
(IQR) method for outlier detection [31]. Accordingly, a practice with the prescribing rate 110 
that fell outside either 1.5 times the IQR below the first quartile or 1.5 times 111 
the IQR above the third quartile, was considered to be an ‘outlier’. We however 112 
acknowledge that a statistical outlier in terms of prescribing rate is not necessarily an 113 
example of inappropriate practice. 114 
The differences in the mean number of prescribing rates, for the rural and urban 115 
practices as well as practices located in areas of different levels of socioeconomic 116 
deprivation, were assessed using an unpaired t-test [31]. The equality of variances of 117 
prescribing rates for above-mentioned practice categories was evaluated using F-test 118 
[30]. The normality of prescribing data was confirmed with Shapiro-Wilks test [32]. 119 
To determine if temporal changes in variability of rates and costs of prescribing 120 
underwent a statistically significant upward or downward trend over the study period, 121 
we used the Mann–Kendall test which has been commonly employed to detect trends 122 
in series of data [33,34].  123 
The relationship between rates and cost of prescribing was explored with Spearman's 124 
rank correlation (rho) [35]. We chose the Spearman correlation measure due to it 125 
insensitivity to individual contribution of outliers. The strength of correlation was 126 
defined as very weak for |rho| = 0.2 to 0.39, moderate for |rho| = 0.4 to 0.59, strong for 127 
|rho| = 0.6 to 0.79, and very strong for |rho| = 0.8 to 1 [35].  128 
Results  129 
The total number of patients registered at 55 general practices providing services 130 
throughout 2013–16 increased from 318,057 in 2013-14 to 326,429 in 2015-16. Over 131 
this time, the total actual prescription cost continued to rise from £58,669,971 in 2013-132 
14 to £63,803,168 in 2015-16.  133 
Fig 1 shows the magnitude and temporal changes in variability of the number of 134 
prescriptions per patient. We observed large differences in drug prescribing rates 135 
among individual practices. The largest between-practice difference in prescribing 136 
rates was observed for the quarter of Apr-Jun 2015, with the number of prescriptions 137 
ranging from 3.34 to 8.36 per patient. During this period, the prescription rate for the 138 
practice with the largest number of prescriptions per patient was ~ 60% higher than 139 
the average prescribing rate for all the practices (µ = 5.20, 95%CI = [4.96,5.44] 140 
prescriptions per patient). The smallest between-practice difference in prescribing 141 
rates was observed in the period Apr-Jun 2013, with the number of prescriptions 142 
ranging from 3.21 to 7.60 per patient. At that time, the practice with the highest 143 
prescribing rate issued ~ 49% more prescriptions per patient compared to the average 144 
prescribing rate of µ = 5.11, 95%CI = [4.89, 5.33]. The high inter-practice variability in 145 
drug prescribing behaviour was caused by: 1.8% (Oct-Dec 2013), 3.6% (Apr-Jun 146 
2013, Oct 2014 -Mar 2016), 5.5% (Jan-Sep 2014), and 7.3% (Jul-Sep 2013) of GP 147 
practices with outlier prescribing rates. By eliminating the effect of these outliers (i.e. 148 
practices with higher or lower prescribing rates than the calculated outlier cut-off 149 
values), we were able to reduce the between-practice variability in prescribing rates 150 
from 21% (σ² reduced from 0.71 to 0.59 in Oct-Dec 2013) up to 70% (σ² reduced from 151 
0.67 to 0.39 in Jul-Sep 2013) (S1 Table). It is worth highlighting that despite varying 152 
number of outliers identified in each quarterly period, they were mostly the same 153 
practices: one practice (with substantially higher prescribing rate than outlier cut-off 154 
values) was identified as an ‘outlier’ throughout the studied period while two other 155 
practices (one with higher and the other with lower prescribing rate than outlier cut-off 156 
values) were labelled as ‘outliers’ at 11 and 4 considered time periods respectively.  157 
Fig 1. Temporal variability in the standardized number of prescriptions. Each data 158 
point (dot): a single practice. Solid, horizontal line inside the box: median of data. 159 
Green diamond: mean. Lower and upper "hinges” of the boxplots: 1st and 3rd quartiles, 160 
respectively. Red, green, and blue lines: trend lines for maximum, average, and 161 
minimum values of prescription rates respectively. Lower and upper extremes of 162 
whiskers: interval boundaries of the non-outliers (black dots). Data outside interval 163 
(red dots): outliers.  164 
Temporal variability in the actual cost of prescribed medications per patient is shown 165 
in Figure 2. The largest between-practice difference in prescribing costs was observed 166 
for the quarter of Apr-Jun 2014, with the prescription cost per patient ranging from 167 
£26.4 to £64.5. During this time period, the highest actual cost of prescribed 168 
medications per patient for the individual practice was ~40% higher than the average 169 
prescribing cost of µ = £46.1, 95%CI = [£45.2, £47.0]. In addition, the average cost 170 
of prescribing per person was observed to increase by 11.3%, 95%CI = 171 
[10.4%,12.2%] over the period of investigation; from £45, 95%CI = [£43.2, £46.8] in 172 
the first quarter (Apr-Jun 2013) to £48.6, 95%CI = [£46.7, £50.6] in the last quarter 173 
(Jan-Mar 2016) of the study.  174 
Fig 2. Temporal variability in the actual cost of prescribed medications per patient. 175 
Each data point (dot): a single practice. Solid, horizontal line inside the box: median of 176 
data. Green diamond: mean. Lower and upper "hinges” of the boxplots: 1st and 3rd 177 
quartiles, respectively. Red, green, and blue lines: trend lines for maximum, average, 178 
and minimum values of prescription costs respectively. 179 
The distribution of costs through time appeared to show a similar trend to the 180 
prescribing rates. The moderate to strong association between prescription rates and 181 
actual costs of prescribed medications was reflected in the value of the Spearman's 182 
coefficient (Fig 3 A). The rho was found to increase from 0.547 in Apr 2013 – Mar 2014 183 
to 0.609 in Apr 2015 – Mar 2016. We also looked at the relationship between 184 
prescribing rates and the actual cost per prescription. We found those two measures 185 
to be moderately correlated (Fig 3 B); the cost per prescription was shown to be lower 186 
for practices with higher rates of prescribing. 187 
Fig 3. The relationship between standardized number of prescriptions and: A) the 188 
actual cost of prescribed medications per patient; B) the actual cost per prescription.  189 
Our trend analysis showed that temporal changes in variability of prescribing rates and 190 
costs underwent an upward trend. Despite some temporal fluctuations in variance, the 191 
best fit line indicates that the value of 𝜎2 for prescribing rates increased from £0.70 in 192 
Apr-Jun 2013 to £0.77 in Jan-Mar 2016 (Fig 4). At the same time, the between-practice 193 
variability in prescribing costs increased from 𝜎2 = £45.6 in Apr-Jun 2013 to 𝜎2 = £53.4 194 
in Jan-Mar 2016. The Mann–Kendall test confirmed a statistically significant upward 195 
trend in variability of GPs prescribing rates (p = 0.011) over the study duration.  196 
Fig 4. Temporal changes in variance calculated for: A) the number of prescriptions per 197 
patient; B) the actual prescription cost per patient for 55 investigated general practices. 198 
Black line represents the best-fit trend line for rates (A) and cost (B) of prescribing.  199 
Rural practices had a lower average number of prescriptions per patient than urban 200 
practices at all time points (Table 1). Over the period of investigation, the mean number 201 
of prescriptions per patient for rural practices rose by ~3.3 % from 5.07, 95CI = 202 
[4.70,5.44] in Apr-Jun 2013 to 5.24, 95CI = [4.83,5.64] in Jan-Mar 2016 while urban 203 
practices reported a ~6.7% increase in average prescribing rate from 5.14, 95CI = 204 
[4.86,5.41] in Apr-Jun 2013 to 5.48, 95CI = [5.22,5.75] in Jan-Mar 2016. In all quarterly 205 
periods, the difference in the mean number of prescribed medications per patient 206 
between urban and rural practices was found statistically insignificant.  207 
Rural practices had a higher between practice variability than urban practices at all 208 
time points (Table 1). The variance for practices designated as rural grew from 𝜎2 = 209 
0.84 in Apr-Jun 2013 to 𝜎2 = 1.02 in Jan-Mar 2016. This upward trend in variability 210 
was found statistically significant with p = 0.0032. Conversely, the variance for urban 211 
practices decreased from 𝜎2 = 0.62 in Apr-Jun 2013 to 𝜎2 = 0.58 in Jan-Mar 2016; 212 
however, this change was statistically insignificant (p = 0.54). At all studied time 213 
periods, F-test p-value showed no significant differences in variance in prescribing 214 
rates between rural and urban practices.  215 
Table 1. Prescribing rates for rural and urban practices. T-test p-value refers to the 216 
significance level of differences in the mean number of prescribing rates between rural 217 
and urban practices for all considered time period. The p-value of F-test assesses the 218 
difference in variances in prescribing rates between rural and urban practices.  219 
Practices situated in more deprived areas were found to have higher prescribing rates 220 
than those located in less deprived areas although this difference was not statistically 221 
significant in any of the considered quarterly periods (Table 2). The average number 222 
of prescriptions per patient in less deprived areas grew by ~7.5% from 5.0, 95CI = 223 
[4.38,5.61] in Apr-Jun 2013 to 5.37, 95CI = [4.76,5.98] in Jan-Mar 2016 while practices 224 
situated in more deprived areas reported a ~4.6% increase in mean prescribing rate 225 
from 5.14, 95CI = [4.92,5.38] in Apr-Jun 2013 to 5.38, 95CI = [5.13,5.62] in Jan-Mar 226 
2016. The variability in prescribing rates for practices in less deprived areas was 227 
substantially higher than for practices in more deprived areas and this difference in 228 
variances was shown to be statistically significant for 8 quarterly periods (Apr 2013-229 
Mar 2015) (Table 2).  230 
Table 2. Prescribing rates for practices located in areas of different levels of socio-231 
economic deprivation. T-test p-value refers to the significance level of differences in 232 
mean number of prescribing rates between practices from less and more deprived 233 
areas. The p-value of F-test assesses the difference in variances in prescribing rates 234 
between practices from less and more deprived areas. Asterisk: Statistically significant 235 
difference (p < 0.05) in variability in prescribing rates.  236 
Discussion 237 
Over the period of investigation, the average between-practice variation in rates of 238 
prescribing was 𝜎2 = 0.74, 95%CI = [0.71, 0.77].  The prescribing rates of individual 239 
practices ranged, on average, from 3.34, 95%CI = [3.26,3.42] to 8, 95%CI = 240 
[7.86,8.14] prescriptions per patient. At the same time, the average variance of 241 
prescribing costs was 𝜎2 = £47.6, 95%CI = [£44.4, £50.8] with actual cost of prescribed 242 
medications per patient ranging, on average, from £27.2, 95%CI = [£26.1, £28.3] to 243 
£67.9, 95%CI = [£66.5, £69.3]. While it may be challenging to define what represents 244 
an appropriate rate or cost of prescribing, it is certainly difficult to justify large 245 
differences in prescribing between individual practices providing care to broadly similar 246 
groups of patients within a single healthcare system.  247 
It is worth highlighting that both rates and costs of prescribing observed in Northern 248 
Ireland Western Health and Social Care Trust were found to be higher than the rates 249 
and costs recorded in England. In 2015, an average of 18.6 items was dispensed in 250 
primary care for each patient registered with a GP practice in England [36] compared 251 
to 21.2 items per head issued in WHSCT. In England, the cost of prescribed items was 252 
roughly £157 per patient, £5 per patient higher than in 2014. In comparison, the 253 
average prescription cost per patient in WHSCT was £189.8, 95%CI = [182.9,196.7], 254 
~£7.6 higher that in 2014. Despite higher average rates of prescribing per patient, the 255 
variation across England in the number of prescribed medications was higher than in 256 
WHSCT with the prescribing rates ranging from 9.5 to 33.3 items per head in 2015. At 257 
the same time, the number of items per patient issued in WHSCT ranged from 13.7 to 258 
31.7 [36]. 259 
Since no demographic data was published alongside the GP prescribing data for 260 
WHSCT, we could not estimate the effect of demographics of patient population on 261 
variation in prescribing rates. Previous studies however showed that demographic 262 
characteristics of patient population did not fully explain prescribing behaviour of GPs 263 
[21]. Among the factors related to the varying prescription activity, age of patients was 264 
most often factored into analyses of variation [37], although age alone did not account 265 
for enough variation to develop an accurate model for predicting prescribing rates [38]. 266 
It was shown that age and gender accounted for approximately 25% of variation 267 
[39,40] and additional demographic characteristics (e.g. mortality rates) up to 51% 268 
[41].  269 
Our study shows differences in both prescribing rates and between practice variation 270 
in prescribing between rural and urban practices. The mean number of prescribed 271 
items was higher in urban practices than in rural practices. The reasons for this are 272 
unclear and were beyond the scope of the present study. However, possible 273 
explanations include differing patient populations in rural and urban areas, differences 274 
in practice organisation and workflow, as well as differences in characteristics of 275 
general practitioners such as training, background, and age. Our results appear 276 
consistent with previous studies. In Scotland, lower levels of prescribing of 277 
antidepressants were found for practices in rural areas while higher rates were 278 
observed for urban practices [18]. In addition, lower rates of prescribing of 279 
psychotropic drugs were reported by rural/small town practices in Denmark [19].  280 
Our results indicate higher levels of prescribing for practices located in more deprived 281 
areas of Western Health and Social Care Trust and lower levels for practices from less 282 
deprived areas. Furthermore, the differences in variances of prescribing rates given 283 
different levels of local deprivation were found statistically significant for 8 quarterly 284 
periods. So far, several studies have demonstrated that socio-economic deprivation 285 
can influence prescription rates for some medications, such as antidepressants and 286 
lipid-lowering drugs. In England, the difference in the number of prescriptions between 287 
the bottom 1% and top 1% areas by deprivation was 20% [42,43]. 288 
In addition, we found that the variability in prescribing rates underwent a statistically 289 
significant upward trend reflecting larger deviations of prescribing rates of individual 290 
practices from the mean prescribing rate. This can be related to the changes in socio-291 
economic and demographic characteristics of patient populations but we also cannot 292 
exclude possibility that these growing deviations may reflect growing differences in 293 
quality of care leading to, in fact, avoidable increase in prescribing costs. However, 294 
higher variability does not necessarily imply lower quality practice. It therefore requires 295 
further inspection to determine if the patient populations associated with specific GP 296 
practices are different and have different needs.  297 
A moderate (Apr 2013-Mar 2015) to strong (Apr 2015-Mar 2016) relationship was 298 
observed between prescription rates and actual costs of prescribing; a higher cost of 299 
prescribed medications per patient was associated with a higher number of issued 300 
items per patient. The differences in pharmaceutical costs observed for the practices 301 
with similar prescription rates might be related to the type of prescribed drugs e.g. the 302 
cost of one pack of Amiodarone (100mg tablets) is £2.21 whereas for a pack of 303 
Allopurinol (100mg tablets), we have to pay over £35. The differences in prescription 304 
costs in practices with similar prescribing rates may also be associated with the 305 
medication choice i.e. a generic vs. brand name drug. There is evidence that inefficient 306 
prescribing by GPs increases NHS costs by hundreds of millions of pounds every year 307 
[21]. Of course, there can be legitimate reasons why patients require brand name 308 
drugs. However, our data do not allow us to examine the appropriateness of such 309 
decisions. We also found the number of items per patient to be negatively correlated 310 
with the cost per item i.e. the cost per prescription was shown to be higher for practices 311 
with lower rates of prescribing. It suggests that practices that prescribe more items per 312 
head appear to prescribe cheaper drugs. 313 
We believe that the identification of outlier practices i.e. practices with higher or lower 314 
prescribing rates than the calculated outlier cut-off values may act as an important 315 
consideration when deciding which practices may benefit from interventions to alter 316 
prescribing behaviour of GPs [44]. That is, there might be greater merit in engaging 317 
with individual practices where prescribing rates appeared significantly higher or lower 318 
than average. The identification of such practices could reduce the time, effort, and 319 
cost of any intervention. However, we are aware that a statistical outlier in terms of 320 
prescribing rates is not equivalent to inappropriate practice and therefore, further 321 
analysis would be required to assess if higher/lower rates than outlier cut off values 322 
can be explained by characteristics of patient populations (e.g. age, ethnicity) or 323 
practice features (e.g. age, training of general practitioners). 324 
The main limitation of our study results from its design. Our analysis was conducted 325 
to investigate the variability patterns and changes in prescribing rates and costs, but 326 
due to data unavailability, we were not able to examine how the differences in patient 327 
or provider factors may affect variation in prescribing. Business Services Organisation 328 
in Northern Ireland does not provide free and open access to data sets related to 329 
demographic characteristics of patient population and practice features at the level of 330 
the GP practice. We believe that when such data becomes available, further 331 
investigation of characteristics of practices and patient populations in Western Health 332 
and Social Care Trust may shed more light on other factors contributing to variations 333 
in GPs prescribing. This can help us to better address potential inappropriateness and 334 
inefficiency of prescribing.  335 
In conclusion, our study provided information on variability patterns and temporal 336 
changes in rates and cost of prescribing in Western Health and Social Care Trust. We 337 
showed that practice setting and socio-economic deprivation account for some of the 338 
between-practice variation in prescribing. We suggest that optimisation of prescribing 339 
could be enhanced by conducting appropriate clinical interventions when other factors 340 
contributing to prescribing variation are identified. These interventions could include 341 
educational initiatives and feedback during which GP practices would be informed 342 
about their own frequency of prescribing relative to the mean prescribing of other 343 
practices. The prescribing behaviour of GPs could also be altered by comparing their 344 
past performance to clearly defined professional standards/targets. The quality 345 
improvement initiatives including normative feedback proved to be effective in 346 
decreasing variability in prescribing in the past [45]. 347 
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Table 1 517 
  
Apr-
Jun 
2013 
Jul-
Sep 
2013 
Oct-
Dec 
2013 
Jan-
Mar 
2014 
Apr-
Jun 
2014 
Jul-
Sep 
2014 
Oct-
Dec 
2014 
Jan-
Mar 
2015 
Apr-
Jun 
2015 
Jul-
Sep 
2015 
Oct-
Dec 
2015 
Jan-
Mar 
2016 
Rural             
Mean 5.07 5.08 5.15 5.16 5.16 5.17 5.26 5.28 5.07 5.11 5.26 5.24 
Variance 0.84 0.74 0.78 0.78 0.78 0.80 0.77 0.87 0.94 0.94 1.07 1.02 
Urban             
Mean 5.14 5.19 5.23 5.23 5.34 5.24 5.39 5.33 5.31 5.43 5.50 5.48 
Variance 0.62 0.62 0.68 0.65 0.68 0.67 0.65 0.62 0.79 0.69 0.68 0.58 
             
F-test p-value  0.41 0.65 0.72 0.63 0.72 0.64 0.66 0.38 0.65 0.41 0.24 0.14 
T-test p-value 0.77 0.64 0.72 0.78 0.44 0.77 0.58 0.83 0.35 0.21 0.36 0.32 
             
518 
Table 2  519 
  
Apr-
Jun 
2013 
Jul-
Sep 
2013 
Oct-
Dec 
2013 
Jan-
Mar 
2014 
Apr-
Jun 
2014 
Jul-
Sep 
2014 
Oct-
Dec 
2014 
Jan-
Mar 
2015 
Apr-
Jun 
2015 
Jul-
Sep 
2015 
Oct-
Dec 
2015 
Jan-
Mar 
2016 
Less deprived areas             
Mean 5.00 5.01 5.12 5.13 5.13 5.11 5.26 5.23 5.22 5.22 5.42 5.37 
Variance 1.27 1.25 1.39 1.37 1.37 1.41 1.31 1.33 1.49 1.41 1.41 1.25 
More deprived areas 
            
Mean 5.14 5.18 5.22 5.22 5.30 5.24 5.36 5.34 5.20 5.31 5.39 5.38 
Variance 0.55 0.51 0.53 0.51 0.54 0.52 0.53 0.56 0.68 0.65 0.70 0.65 
             
F-test p-value  0.046* 0.031* 0.022* 0.018* 0.027* 0.018* 0.032* 0.037* 0.065 0.066 0.096 0.117 
T-test p-value 0.665 0.625 0.776 0.788 0.624 0.709 0.770 0.767 0.966 0.790 0.926 0.979 
             
S1 Table. The variance in prescribing rates for the data set with and without outlier practices. 
 
  
Apr-
Jun 
2013 
Jul-
Sep 
2013 
Oct-
Dec 
2013 
Jan-
Mar 
2014 
Apr-
Jun 
2014 
Jul-
Sep 
2014 
Oct-
Dec 
2014 
Jan-
Mar 
2015 
Apr-
Jun 
2015 
Jul-
Sep 
2015 
Oct-
Dec 
2015 
Jan-
Mar 
2016 
With outlier practices             
𝜎2 (£) 0.70 0.67 0.71 0.69 0.72 0.71 0.70 0.72 0.85 0.81 0.85 0.77 
Without outlier practices 
            
𝜎2 (£) 0.52 0.39 0.59 0.43 0.45 0.44 0.49 0.50 0.60 0.58 0.59 0.56 
 
